Given these observations, a monoclonal antibody bispecific for CD133 and EGFRvIII was constructed: this antibody induced cytotoxicity of glioblastoma cells and reduced their tumorigenic potential [26]. This evidence concerns the gene PROM1 and glioblastoma.